AMSTERDAM (GenomeWeb) – A Cepheid executive today provided an update on upcoming improvements to various Xpert real-time PCR-based molecular assays and outlined a new partnering program that aims to validate and commercialize third-party assays on the company's Xpert microfluidic test cartridges.

In addition, an early user of a new Xpert-based Mycoplasma genitalium and antibiotic resistance test from SpeeDx, Cepheid's first cartridge partner, shared initial validation data on the assay.